Objectives: This presentation aims to explore the efficacy and safety of our enhanced treatment protocol in treating Androgenetic Alopecia. Our enhanced treatment protocol is comprised of three different enhancement methods to the currently available treatments of Androgenetic Alopecia. The first method of enhancement is by utilizing devices eg. Microneedling. The second method of enhancement is by combining different medications at the same time. The third method of enhancement is by introducing a non-medication approach utilizing patient’s blood to acquire Platelet Rich Plasma (PRP).
Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss in the world affecting men and women. AGA is typically distributed in genetically susceptible men and women and may present as early as pubertal age. This condition has no permanent cure and require a lifelong therapy. Currently, topical minoxidil, oral finasteride, and Low-Level Laser Light therapy are the three treatment options approved by the FDA. Multiple studies have been conducted, but unfortunately efficacy is not high and enhancements to the currently available options are still needed.
Materials / method: 20 male patients were enrolled in this study. All patients have been diagnosed with Androgenetic alopecia and have not had any medical treatments within the past 3 months. We divide the patient into 2 groups, 10 patients were treated using only topical minoxidil, and the remainder were given our enhanced treatment protocol in addition to the topical minoxidil. Both groups were given treatment for 12 weeks. Global photographs and dermoscopic assessments were performed prior to treatment and after treatment sessions.
Results: Significant increase in hair density were found in both groups. The enhanced treatment protocol group had higher degree of improvement compared to the monotherapy group without any severe adverse effects.
Conclusion: The enhanced treatment protocol is a safe yet more efficacious treatment option in treating Androgenetic Alopecia.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No
This work was not supported by any direct or non direct funding. It is under the author's own responsability
